PAQ to Present First Clinical Data for KRAS G12D Degrader PT0253
Image
Burlington – November 03, 2026 -- PAQ Therapeutics will present the first clinical data for PT0253, its selective KRAS G12D degrader, in a late-breaking oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain, on November 20.
Phase 1 data in advanced solid tumors will cover safety and antitumor activity
The presentation reports findings from the company's ongoing Phase 1 trial in patients with advanced solid tumors. The abstract title (6LBA) describes a differentiated safety profile and antitumor activity for PT0253, including in patients who received prior (K)RAS-targeted therapy.
The slot is scheduled for 12:36-12:44 p.m. CET in Plenary Session 6, "Proffered Papers: Advances in Targeting RAS." ENA 2026 runs November 18-20.